Literature DB >> 527870

Clq metabolism in ulcerative colitis and Crohn's disease.

B J Potter, H J Hodgson, A S Mee, D P Jewell.   

Abstract

The metabolism of pure radioiodine labelled Clq has been observed in five patients with ulcerative colitis, five patients with Crohn's disease, and in five control subjects. Both the fractional catabolic rate and the synthesis rate of Clq were increased in the five patients with Crohn's disease and in four of the five patients with ulcerative colitis. The fifth patient was in remission and had a normal synthesis rate. These results support the hypothesis that complement activation plays a role in the pathogenesis of these disease states and that the increased complement activation is primarily via the classical pathway.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 527870      PMCID: PMC1412679          DOI: 10.1136/gut.20.11.1012

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  19 in total

1.  Immune complexes in ulcerative colitis and Crohn's disease.

Authors:  H J Hodgson; B J Potter; D P Jewell
Journal:  Clin Exp Immunol       Date:  1977-08       Impact factor: 4.330

2.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

3.  Evidence for complement-binding immune complexes in adult coeliac disease, Crohn's disease, and ulcerative colitis.

Authors:  W F Doe; C C Booth; D L Brown
Journal:  Lancet       Date:  1973-02-24       Impact factor: 79.321

4.  Circulating immune complexes in dermatitis herpetiformis.

Authors:  J F Mowbray; A V Hoffbrand; E J Holborow; P P Seah; L Fry
Journal:  Lancet       Date:  1973-02-24       Impact factor: 79.321

5.  Antibacterial antibodies in rectal and colonic mucosa in ulcerative colitis.

Authors:  E Monteiro; J Fossey; M Shiner; B S Drasar; A C Allison
Journal:  Lancet       Date:  1971-02-06       Impact factor: 79.321

6.  Circulating immune complexes in inflammatory bowel disease.

Authors:  D P Jewell; I C MacLennan
Journal:  Clin Exp Immunol       Date:  1973-06       Impact factor: 4.330

7.  Proceedings: Serum complement components C3 and C4 in inflammatory bowel disease.

Authors:  M Ward; M A Eastwood
Journal:  Gut       Date:  1974-10       Impact factor: 23.059

8.  Humoral immune system in inflammatory bowel disease: I. Complement levels.

Authors:  H J Hodgson; B J Potter; D P Jewell
Journal:  Gut       Date:  1977-09       Impact factor: 23.059

9.  In vitro synthesis of immunoglobulins, secretory component, complement and lysozyme by human gastrointestinal tissues. II. Pathological tissues.

Authors:  D B McClelland; D J Shearman; R F Lai A Fat; R van Furth
Journal:  Clin Exp Immunol       Date:  1976-01       Impact factor: 4.330

10.  Immune-complex mediated colitis in rabbits. An experimental model.

Authors:  H J Hodgson; B J Potter; J Skinner; D P Jewell
Journal:  Gut       Date:  1978-03       Impact factor: 23.059

View more
  2 in total

1.  Circulating immune complexes in Crohn's disease. Their characterization and interrelationship with components of the complement system.

Authors:  E R Richens; C M Thorp; P W Bland; N D Hall
Journal:  Dig Dis Sci       Date:  1982-02       Impact factor: 3.199

2.  Complement inhibitors and immunoconglutinins in ulcerative colitis and Crohn's disease.

Authors:  B J Potter; D J Brown; A Watson; D P Jewell
Journal:  Gut       Date:  1980-12       Impact factor: 23.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.